Moleculin Biotech, Inc. Board of Directors

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Mr. Walter V. Klemp

Mr. Walter V. Klemp

Co-Founder, Chairman, President & CEO

Dr. John Paul Waymack M.D., Sc.D.

Dr. John Paul Waymack M.D., Sc.D.

Senior Chief Medical Officer

Dr. Donald H. Picker Ph.D.

Dr. Donald H. Picker Ph.D.

Chief Scientific Officer

Dr. Waldemar Priebe Ph.D.

Dr. Waldemar Priebe Ph.D.

Co-Founder, Founding Scientist & Chairman of Scientific Advisory Board

Dr. Sandra L. Silberman M.D., Ph.D.

Dr. Sandra L. Silberman M.D., Ph.D.

Chief Medical Officer of New Products

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.